BPL-003 Phase 2b Clinical Trial Results - The open-label extension of the BPL-003 Phase 2b clinical trial demonstrated additional and durable antidepressant effects after a second dose[11] - Patients who received an active dose (either 8 mg or 12 mg) of BPL-003 in the core study achieved a response rate of 63% and a remission rate of 48% at Week 8 (Week 16 of the Phase 2b clinical trial)[11] - In the core study, statistically significant MADRS difference was observed at Day 29 (Week 4) following a single 8 mg or 12 mg dose vs 0.3 mg[21] - In the core study, 8 mg dose demonstrated comparable efficacy to 12 mg, suggesting it may be sufficient to achieve maximal therapeutic benefit[21] - In the OLE study, patients who received an active dose in the core study showed a mean reduction in MADRS score of 19.0 points at Day 57 compared to baseline at the start of the Phase 2b clinical trial[36] - In the OLE study, responder rates continued to improve following a second dose of BPL-003[37] - In the OLE study, remission rates continued to improve following a second dose of BPL-003[40] Safety and Tolerability - BPL-003 was generally well-tolerated, with the majority of TEAEs occurring on the day of dosing, classified as mild or moderate, and transient in nature[11] - In the core study, 78% of participants experienced any TEAE[24] - In the OLE study, 86% of participants experienced any TEAE[43] Market Opportunity - Spravato achieved blockbuster status and established the 2-hour in-clinic interventional psychiatry treatment paradigm[50] - Spravato reported global annual sales of $1.047 billion in Q1-Q3 2025[51]

Financial Performance & Acquisitions - Strata's Q3 2025 revenue reached $493 million, a 37% year-over-year increase, with 29% organic growth excluding the Keystone acquisition[5] - The acquisition of Keystone Perfusion contributed approximately $28 million to Strata's Q3 2025 revenue[6] - Adjusted EBITDA for Q3 2025 was $42 million, representing an 85% margin[5] - Strata sold its passenger business to Joby Aviation for $125 million[14] - Strata acquired Keystone Perfusion for $124 million upfront, with potential earn-outs of $23 million based on gross profit targets[15] Market Position & Growth Strategy - Strata estimates its market share to be approximately 30% in air logistics and 15% in ground logistics for organ transport[11] - The company is focused on expanding its transplant clinical services, particularly Normothermic Regional Perfusion (NRP), driven by a 20%+ CAGR in Donation after Circulatory Death (DCD) donors[43] - Strata aims to increase aircraft utilization and improve operating costs by expanding into other time-critical logistics verticals[55] Organ Transplant Trends - The distance of heart, liver, and lung transplants has increased by 64% from 2018 to 2024 due to regulatory changes and new technologies[39] - Normothermic Regional Perfusion (NRP) penetration of DCD donors has increased to approximately 40% by Q3 2025[43] - U S heart, liver, and lung transplants have grown at a CAGR of 38% from 2010-2024[27]

Q3 2025 Highlights - Dole's broadly based business model delivered a good Q3 2025 result, in line with market expectations[9] - The company completed the sale of its Fresh Vegetable division at the beginning of August for $140 million[9] - The board authorized share repurchases of up to $100 million[9] Financial Performance - Q3 2025 revenue increased to $2,279 million, compared to $2,062 million in Q3 2024[25] - Income from continuing operations for Q3 2025 was $241 million, up from $151 million in Q3 2024[25] - Net income attributable to Dole plc decreased to $51 million in Q3 2025, from $144 million in Q3 2024[25] - Adjusted EBITDA for Q3 2025 was $808 million, slightly down from $821 million in Q3 2024[25] Segment Results - Fresh Fruit revenue increased by 115% to $890 million, but Adjusted EBITDA decreased by 367% to $272 million due to higher sourcing costs[28] - Diversified Fresh Produce – EMEA revenue increased by 109% to $998 million, and Adjusted EBITDA increased by 342% to $407 million[32] - Diversified Fresh Produce – Americas & ROW revenue increased by 77% to $420 million, and Adjusted EBITDA increased by 462% to $129 million[37] FY'25 Outlook - The company is targeting the upper end of the $380-$390 million range for Adjusted EBITDA from continuing operations[46] - Routine capital expenditure for continuing operations is expected to be approximately $85 million[46]

LSEG Group Strategy and Performance - LSEG's diversified business model delivers strong financial performance, with 73% high-quality recurring revenues and structurally growing transactional revenues[26, 27] - LSEG has a track record of uncorrelated, all-weather growth, delivering Earnings per Share (EPS) CAGR of 15% and Dividend per Share (DPS) CAGR of 18% over the last 20 years[32, 34] - Free cash flow continues to trend upward, expected to hit £2.4 billion in 2025[36] - LSEG has delivered £292 million revenue and £562 million cost synergies[48] Data & Analytics Strategy and Monetization - Data & Analytics represents 47% of LSEG's £3.9 billion income in 2024[13] - LDAs are forecast to account for 17% of D&A ASV by the end of 2025[68] - Tick History is experiencing 39% p a growth in use[155] - Since 2021, D&A revenue growth has been accelerating, with >5 0% organic constant currency growth expected in FY2025[161] AI Strategy and Engineering Transformation - LSEG is the global 1 in real-time data[107] - LSEG's engineering transformation strategy focuses on Exceptional Talent, Common Platforms, and Product Discipline to accelerate product development and AI adoption[92, 93] - LSEG is transforming data onboarding and customer operations with AI, achieving results such as 9x faster content extraction and a 51% FTE reduction in the central sourcing team[127, 128] New Products and Services - ForexClear clears only 1% of the FX market, driven by FX Options and NDFs, which are subject to the Uncleared Margin Rules (UMR), generating over £50 million in annual revenue[380] - The Private Securities Market (PSM) charges companies an admission fee of £25,000 a year for access to 2 auctions, buyers will pay 0 75% on value of shares bought, sellers will pay 1% on value of shares sold[360, 361]

(NASDAQ: VIOT) Company Presentation Safe Harbor Statement This presentation has been prepared by Viomi Technology Co., Ltd ("Viomi" or the "Company") solely for informational purposes and does not constitute an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company in any jurisdiction or an inducement to enter into investment activity, nor may it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. This docu ...

Financial Performance - LINZESS U S net sales reached $315 million in Q3 2025, a 40% year-over-year increase, driven by improved net pricing and a 12% year-over-year growth in EUTRx demand[11] - Ironwood generated $40 million in GAAP net income and $82 million in adjusted EBITDA in Q3 2025[11] - The company's share of net profit from the LINZESS U S brand collaboration was $119 515 million for the three months ended September 30, 2025[15] - Ironwood's collaborative arrangements revenue was $119 646 million for the three months ended September 30, 2025[15] - Ironwood ended Q3 2025 with $140 million in cash and cash equivalents[11] Guidance and Expectations - Full-year LINZESS U S net sales guidance was raised to $860 - $890 million, and total revenue guidance to $290 - $310 million[11] - Adjusted EBITDA guidance was raised to greater than $135 million[11] LINZESS Performance - LINZESS extended unit (EUTRx) and new to brand (NBRx) prescriptions each grew 12% year-over-year in Q3 2025[12] - LINZESS U S net product sales as reported by AbbVie were $314 856 million for the three months ended September 30, 2025[15] Strategic Developments - In November 2025, the FDA approved LINZESS as the first drug for the treatment of children 7 years and older with irritable bowel syndrome with constipation (IBS-C)[11] - The company plans to align with the FDA in Q4 2025 on confirmatory Phase 3 trial design for Apraglutide, with trial initiation expected in 1H 2026[7]

Financial Performance - VEON delivered strong revenue growth of 7.5% in USD and 11% in local currency (LCY), outpacing inflation at 8.4%[11] - EBITDA grew by 19.7% in USD and 24.2% in LCY[11, 20] - Direct digital revenues increased significantly by 63.1% in USD, representing 17.8% of total revenues[11] - LTM equity free cash flow (FCF) reached $584 million, demonstrating sustained FCF momentum[12, 13] - Earnings per ADS increased by 73.6% to $7.81 for 9M25 and by 60.2% to $8.89 for LTM[13] Digital Growth and Strategy - Digital engagement is accelerating, surpassing mobile engagement in monthly usage[12] - VEON is integrating AI-powered features into its digital applications[12] - The company is committed to the combined power of DO1440 and AI1440[12] - Total digital monthly active users (MAU) reached 143.3 million, a 39.3% year-over-year increase[28] Strategic Initiatives - VEON completed the sale of its Kyrgyzstan business[12] - The company is advancing infrastructure monetization across all markets[12] - VEON pioneered Direct to Cell satellite connectivity in its markets[12] - A new buyback plan of up to $100 million of ADS and/or bonds was announced[12] Regional Performance - Pakistan's total revenue increased by 14.6% in LCY, with direct digital revenue up by 28.5%[24] - Ukraine's total revenue grew by 21.1% in LCY, with direct digital revenue increasing 5.3x[24] - Kazakhstan's total revenue increased by 6.7% in LCY, with direct digital revenue up by 43.1%[24] - Uzbekistan's total revenue increased by 9.3% in LCY, with direct digital revenue increasing 2.4x[24]

Financial Performance Highlights - FY2025 net sales reached $1,430 million, with a 5-year CAGR of 8.2%[12] - Adjusted EBITDA for FY2025 was $326.2 million, representing 22.8% of net sales and a 5-year CAGR of 11.3%[12] - Free cash flow for FY2025 amounted to $172 million[12] - Net debt stood at $20.1 million as of September 30, 2025, with a net debt to adjusted EBITDA ratio of 0.1x[12] - Q4 Fiscal 2025 net sales were $380.8 million, a 9.4% increase year-over-year[71] - Q4 Fiscal 2025 adjusted EBITDA was $91.8 million, a 26.6% increase year-over-year[71] - Q4 Fiscal 2025 adjusted net income per diluted share was $0.38, a 72.7% increase year-over-year[71] Strategic Priorities and Investments - The company aims to identify a total of 18 billion gallons of water loss by 2029 through EchoShore® leak detection[20] - Capital expenditures are expected to increase to 4% to 5% of net sales over the next 3 years[77] - The company has allocated $95 million to share repurchases since FY2019, including $15 million in FY2025, with $65 million remaining authorization on the share repurchase program as of September 30, 2025[93] FY2026 Outlook - Consolidated net sales are projected to be between $1,450 million and $1,470 million, representing a year-over-year growth of 1.4% to 2.8%[87] - Adjusted EBITDA is expected to range from $345 million to $350 million, indicating a year-over-year growth of 5.8% to 7.3%[87]

Investor Presentation (NASDAQ: CBAT) Technology, Inc. November 2025 CBAK Energy ©2025 CBAK. All Rights Reserved. The First Chinese Li-ion Battery Manufacturer Listed in NASDAQ Disclaimer Powering a Sustainable Life with Electricity Disclaimers and Other Important Information This presentation (the "Presentation") about CBAK Energy Technology, Inc. (the "Company" or "CBAK") is dated as of March 2021. It is information in a summary form and does not purport to be complete. The data contained herein is derived ...

Company Overview - Standard Lithium aims to be a leading low-cost, sustainable U S lithium producer [22] - The company plans for near-term commercial-scale production using innovative technologies on its Arkansas and Texas assets [24] - The company is developing projects with global partners, benefiting from stakeholder and regulatory support [26] Resource and Project Highlights - The Smackover Formation is a premier lithium resource in North America, with concentrations up to 616 mg/L in Arkansas and 806 mg/L in East Texas [27] - The South West Arkansas (SWA) Project has been awarded a $225 million grant from the U S Department of Energy (DOE) [27] - The SWA Project is targeting commercial production in 2028, with an initial capacity of 22,500 tonnes per annum (TPA) of lithium carbonate [30, 38] - The East Texas Projects have the potential for over 100,000 TPA LCE production across three projects [38] Market and Economics - Global lithium demand is projected to reach 2.8 million tonnes of lithium carbonate equivalent (LCE) by 2030 [27] - The SWA Project DFS indicates a $1.7 billion unlevered pre-tax NPV and a 20% pre-tax IRR, with a total CAPEX of $1.449 billion [40]